Aegerion Pharmaceuticals to Present at the Citi 2012 Global Healthcare Conference


CAMBRIDGE, Mass., Feb. 22, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today that the company will participate in the Citi 2012 Global Healthcare Conference in New York City. Marc Beer, Chief Executive Officer of Aegerion, is scheduled to present on Monday, February 27, 2012 at 3:30 p.m. ET.

The presentation will be webcast live and may be accessed for 90 days following the conference by visiting the "Investors" section of Aegerion's website, www.aegerion.com.

About Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The Company's lead product, lomitapide, is in development to treat patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The Company also plans to initiate a clinical program for lomitapide to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia.



            

Contact Data